Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunvozertinib + golidocitinib
- Development stage
- Phase 2
- Lead developer
- Dizal Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sunvozertinib (DZD9008) is a selective, irreversible small molecule inhibitor of the epidermal growth factor receptor (EGFR), specifically designed to target EGFR exon 20 insertion mutations and HER2 mutations. It is being developed primarily for the treatment of non-small cell lung cancer (NSCLC) with these genetic alterations. Golidocitinib (DZD4205, previously known as AZD4205) is an orally available, potent and highly selective Janus kinase 1 (JAK1) inhibitor under development for oncology indications, including NSCLC and peripheral T-cell lymphoma. The combination of sunvozertinib and golidocitinib is being investigated in clinical trials for patients with NSCLC who have failed standard treatments and harbor EGFR mutations[4][6][7].
- Other names
- sunvozertinib + golidocitinib
02
Targets
EGFR ex20ins (Epidermal growth factor receptor exon 20 mutant)JAK1 (Janus kinase 1)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on sunvozertinib + golidocitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunvozertinib + golidocitinib.